{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:57:58Z","timestamp":1789747078828,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Project of National Natural Science Foundation of China","award":["82230088"],"award-info":[{"award-number":["82230088"]}]},{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["20Z11900200"],"award-info":[{"award-number":["20Z11900200"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research","award":["2019CXJQ01"],"award-info":[{"award-number":["2019CXJQ01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds<\/jats:title>\n                    <jats:p>Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses to ICB due in part to the lack of an immunogenic niche. Focal adhesion kinase (FAK) is frequently amplified and acts as an immune modulator across cancer types. However, evidence illustrates that targeting FAK is most effective in combination therapy rather than in monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we used drug screening, in vitro and in vivo assays to filter out that doxorubicin and its liposomal form pegylated liposome doxorubicin (PLD) showed synergistic anti-tumor effects in combination with FAK inhibitor IN10018. We hypothesized that anti-tumor immunity and immunogenic cell death (ICD) may be involved in the treatment outcomes through the data analysis of our clinical trial testing the combination of IN10018 and PLD. We then performed cell-based assays and animal studies to detect whether FAK inhibition by IN10018 can boost the ICD of PLD\/doxorubicin and further established syngeneic models to test the antitumor effect of triplet combination of PLD, IN10018, and ICB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrated that the combination of FAK inhibitor IN10018, and PLD\/doxorubicin exerted effective antitumor activity. Notably, the doublet combination regimen exhibited response latency and long-lasting treatment effects clinically, outcomes frequently observed in immunotherapy. Our preclinical study confirmed that the 2-drug combination can maximize the ICD of cancer cells. This approach primed the tumor microenvironment, supplementing it with sufficient tumor-infiltrating lymphocytes (TILs) to activate antitumor immunity. Finally, different animal studies confirmed that the antitumor effects of ICB can be significantly enhanced by this doublet regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We confirmed that targeting FAK by IN10018 can enhance the ICD of PLD\/doxorubicin, further benefiting the anti-tumor effect of ICB. The animal tests of the triplet regimen warrant further discovery in the real world.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-02974-4","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T01:02:12Z","timestamp":1708304532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade"],"prefix":"10.1186","volume":"43","author":[{"given":"Baoyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruibao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"issue":"2","key":"2974_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/0008-5472.CAN-18-3539","volume":"80","author":"T Navas","year":"2020","unstructured":"Navas T, Kinders RJ, Lawrence SM, et al. Clinical evolution of epithelial-mesenchymal transition in human carcinomas. Cancer Res. 2020;80(2):304\u201318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3539. [publishedOnlineFirst:2019\/11\/17].","journal-title":"Cancer Res"},{"issue":"1","key":"2974_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. https:\/\/doi.org\/10.1186\/s12943-019-1091-2. [publishedOnlineFirst:2019\/11\/07].","journal-title":"Mol Cancer"},{"key":"2974_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12916-016-0571-0","volume":"14","author":"JM Redman","year":"2016","unstructured":"Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med. 2016;14:20. https:\/\/doi.org\/10.1186\/s12916-016-0571-0. [publishedOnlineFirst:20160206].","journal-title":"BMC Med"},{"issue":"9","key":"2974_CR4","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","volume":"126","author":"AI Daud","year":"2016","unstructured":"Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447\u201352. https:\/\/doi.org\/10.1172\/JCI87324. [publishedOnlineFirst:2016\/08\/16].","journal-title":"J Clin Invest"},{"issue":"4","key":"2974_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41568-021-00343-3","volume":"21","author":"A York","year":"2021","unstructured":"York A. Overcoming hurdles in cancer immunotherapy. Nat Rev Cancer. 2021;21(4):214\u20135. https:\/\/doi.org\/10.1038\/s41568-021-00343-3. [publishedOnlineFirst:2021\/02\/24].","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2974_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860\u201375. https:\/\/doi.org\/10.1038\/nrc3380. [publishedOnlineFirst:2012\/11\/16].","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2974_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/onc.2012.130","volume":"32","author":"B Luo","year":"2013","unstructured":"Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;32(7):805\u201318. https:\/\/doi.org\/10.1038\/onc.2012.130. [publishedOnlineFirst:20120416].","journal-title":"Oncogene"},{"issue":"12","key":"2974_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buque A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z. [publishedOnlineFirst:2020\/08\/08].","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2974_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.neo.2015.08.004","volume":"17","author":"J Rios-Doria","year":"2015","unstructured":"Rios-Doria J, Durham N, Wetzel L, et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia. 2015;17(8):661\u201370. https:\/\/doi.org\/10.1016\/j.neo.2015.08.004. [publishedOnlineFirst:2015\/09\/27].","journal-title":"Neoplasia"},{"issue":"12","key":"2974_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691\u2013701. https:\/\/doi.org\/10.1084\/jem.20050915.","journal-title":"J Exp Med"},{"issue":"12","key":"2974_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","volume":"24","author":"DN Waterhouse","year":"2001","unstructured":"Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001;24(12):903\u201320. https:\/\/doi.org\/10.2165\/00002018-200124120-00004.","journal-title":"Drug Saf"},{"issue":"7","key":"2974_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22(7):1034\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(21)00216-3. [publishedOnlineFirst:20210615].","journal-title":"Lancet Oncol"},{"issue":"4","key":"2974_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccell.2015.03.013","volume":"27","author":"MC Frame","year":"2015","unstructured":"Frame MC, Serrels A. FAK to the rescue: activated stroma promotes a \u201csafe haven\u201d for BRAF-mutant melanoma cells by inducing FAK signaling. Cancer Cell. 2015;27(4):429\u201331. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.013. [publishedOnlineFirst:2015\/04\/16].","journal-title":"Cancer Cell"},{"issue":"8","key":"2974_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851\u201360. https:\/\/doi.org\/10.1038\/nm.4123. [publishedOnlineFirst:2016\/07\/05].","journal-title":"Nat Med"},{"issue":"1","key":"2974_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41523-021-00263-3","volume":"7","author":"S Timbrell","year":"2021","unstructured":"Timbrell S, Aglan H, Cramer A, et al. FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity. NPJ Breast Cancer. 2021;7(1):65. https:\/\/doi.org\/10.1038\/s41523-021-00263-3. [publishedOnlineFirst:20210528].","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"2974_CR16","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.3390\/ijms23126381","volume":"23","author":"A Spallarossa","year":"2022","unstructured":"Spallarossa A, Tasso B, Russo E, et al. The Development of FAK Inhibitors: A Five-Year Update. Int J Mol Sci. 2022;23(12):6381. https:\/\/doi.org\/10.3390\/ijms23126381. [published Online First: 20220607].","journal-title":"Int J Mol Sci"},{"issue":"16","key":"2974_CR17","doi-asserted-by":"publisher","first-page":"e2100250","DOI":"10.1002\/advs.202100250","volume":"8","author":"B Zhang","year":"2021","unstructured":"Zhang B, Zhang Y, Zhang J, et al. Focal Adhesion Kinase (FAK) inhibition synergizes with KRAS G12C Inhibitors in treating cancer through the regulation of the FAK-YAP Signaling. Adv Sci (Weinh). 2021;8(16):e2100250. https:\/\/doi.org\/10.1002\/advs.202100250. [publishedOnlineFirst:20210620].","journal-title":"Adv Sci (Weinh)"},{"issue":"23","key":"2974_CR18","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1158\/1078-0432.CCR-15-2603","volume":"22","author":"KJ Tang","year":"2016","unstructured":"Tang KJ, Constanzo JD, Venkateswaran N, et al. Focal adhesion kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer. Clin Cancer Res. 2016;22(23):5851\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2603. [publishedOnlineFirst:2016\/05\/26].","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2974_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson JC, Serrels A, Stupack DG, et al. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021;21(5):313\u201324. https:\/\/doi.org\/10.1038\/s41568-021-00340-6. [publishedOnlineFirst:2021\/03\/19].","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2974_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/13543776.2018.1414183","volume":"28","author":"PC Lv","year":"2018","unstructured":"Lv PC, Jiang AQ, Zhang WM, Zhu HL. FAK inhibitors in Cancer, a patent review. Expert Opin Ther Pat. 2018;28(2):139\u201345. https:\/\/doi.org\/10.1080\/13543776.2018.1414183. [publishedOnlineFirst:2017\/12\/07].","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"2974_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41389-018-0083-1","volume":"7","author":"S Tiede","year":"2018","unstructured":"Tiede S, Meyer-Schaller N, Kalathur RKR, et al. The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis. 2018;7(9):73. https:\/\/doi.org\/10.1038\/s41389-018-0083-1. [publishedOnlineFirst:2018\/09\/22].","journal-title":"Oncogenesis"},{"issue":"2","key":"2974_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41389-018-0032-z","volume":"7","author":"UA Hirt","year":"2018","unstructured":"Hirt UA, Waizenegger IC, Schweifer N, et al. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018;7(2):21. https:\/\/doi.org\/10.1038\/s41389-018-0032-z. [publishedOnlineFirst:2018\/02\/24].","journal-title":"Oncogenesis"},{"issue":"16_suppl","key":"2974_CR23","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1200\/JCO.2022.40.16_suppl.5567","volume":"40","author":"L Wu","year":"2022","unstructured":"Wu L, Wang J, Wang L, et al. A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2022;40(16_suppl):5567\u201367. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5567.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2974_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","volume":"159","author":"EK Lee","year":"2020","unstructured":"Lee EK, Xiong N, Cheng SC, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial. Gynecol Oncol. 2020;159(1):72\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.028. [publishedOnlineFirst:20200806].","journal-title":"Gynecol Oncol"},{"key":"2974_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/edbk_200643","volume":"38","author":"E Borcoman","year":"2018","unstructured":"Borcoman E, Nandikolla A, Long G, et al. Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book. 2018;38:169\u201378. https:\/\/doi.org\/10.1200\/edbk_200643.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"2974_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2017.01.005","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Zhao W, Akbani R, et al. characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell. 2017;31(2):225\u201339. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.005.","journal-title":"Cancer Cell"},{"issue":"5","key":"2974_CR27","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154(5):1151\u201361. https:\/\/doi.org\/10.1016\/j.cell.2013.08.003.","journal-title":"Cell"},{"issue":"1","key":"2974_CR28","doi-asserted-by":"publisher","first-page":"e10166","DOI":"10.1002\/btm2.10166","volume":"6","author":"DC Pan","year":"2021","unstructured":"Pan DC, Krishnan V, Salinas AK, et al. Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioeng Transl Med. 2021;6(1) [publishedOnlineFirst:20200528].","journal-title":"Bioeng Transl Med"},{"issue":"3","key":"2974_CR29","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7150\/ijms.39172","volume":"17","author":"K Li","year":"2020","unstructured":"Li K, Zhan W, Jia M, et al. Dual Loading of nanoparticles with doxorubicin and icotinib for the synergistic suppression of non-small cell lung cancer. Int J Med Sci. 2020;17(3):390\u2013402. https:\/\/doi.org\/10.7150\/ijms.39172. [publishedOnlineFirst:20200204].","journal-title":"Int J Med Sci"},{"key":"2974_CR30","doi-asserted-by":"publisher","first-page":"456409","DOI":"10.1155\/2013\/456409","volume":"2013","author":"J Lao","year":"2013","unstructured":"Lao J, Madani J, Puertolas T, et al. Liposomal Doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013;2013:456409. https:\/\/doi.org\/10.1155\/2013\/456409. [publishedOnlineFirst:20130326].","journal-title":"J Drug Deliv"},{"key":"2974_CR31","doi-asserted-by":"publisher","first-page":"153303382110421","DOI":"10.1177\/15330338211042139","volume":"20","author":"K Schlick","year":"2021","unstructured":"Schlick K, Kiem D, Huemer F, et al. Non-pegylated liposomal doxorubicin as palliative chemotherapy in pre-treated advanced pancreatic cancer: a retrospective analysis of twenty-eight patients. Technol Cancer Res Treat. 2021;20:15330338211042140. https:\/\/doi.org\/10.1177\/15330338211042139.","journal-title":"Technol Cancer Res Treat"},{"issue":"11","key":"2974_CR32","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1200\/JCO.1999.17.11.3512","volume":"17","author":"MI Koukourakis","year":"1999","unstructured":"Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol. 1999;17(11):3512\u201321. https:\/\/doi.org\/10.1200\/JCO.1999.17.11.3512.","journal-title":"J Clin Oncol"},{"issue":"31","key":"2974_CR33","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541\u20133. https:\/\/doi.org\/10.1200\/JCO.2015.61.6870. [publishedOnlineFirst:20150810].","journal-title":"J Clin Oncol"},{"issue":"2","key":"2974_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"12","key":"2974_CR35","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1001\/jamaoncol.2021.4971","volume":"7","author":"RB Parikh","year":"2021","unstructured":"Parikh RB, Min EJ, Wileyto EP, et al. Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers. Jama Oncol. 2021;7(12):1843\u201350. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4971.","journal-title":"Jama Oncol"},{"issue":"7520","key":"2974_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature13541","volume":"514","author":"B Tavora","year":"2014","unstructured":"Tavora B, Reynolds LE, Batista S, et al. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature. 2014;514(7520):112\u20136. https:\/\/doi.org\/10.1038\/nature13541. [publishedOnlineFirst:2014\/08\/01].","journal-title":"Nature"},{"issue":"1","key":"2974_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/nar\/gkr687","volume":"40","author":"M Volcic","year":"2012","unstructured":"Volcic M, Karl S, Baumann B, et al. NF-kappaB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res. 2012;40(1):181\u201395. https:\/\/doi.org\/10.1093\/nar\/gkr687. [publishedOnlineFirst:20110909].","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2974_CR38","doi-asserted-by":"publisher","first-page":"D613","DOI":"10.1093\/nar\/gkaa1024","volume":"49","author":"M Martens","year":"2021","unstructured":"Martens M, Ammar A, Riutta A, et al. WikiPathways: connecting communities. Nucleic Acids Res. 2021;49(D1):D613\u201321. https:\/\/doi.org\/10.1093\/nar\/gkaa1024.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2974_CR39","doi-asserted-by":"publisher","first-page":"110244","DOI":"10.1016\/j.celrep.2021.110244","volume":"38","author":"F Catala-Moll","year":"2022","unstructured":"Catala-Moll F, Ferrete-Bonastre AG, Godoy-Tena G, et al. Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis. Cell Rep. 2022;38(3):110244. https:\/\/doi.org\/10.1016\/j.celrep.2021.110244.","journal-title":"Cell Rep"},{"issue":"18","key":"2974_CR40","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/0008-5472.CAN-15-1122","volume":"75","author":"H Yang","year":"2015","unstructured":"Yang H, Yamazaki T, Pietrocola F, et al. STAT3 Inhibition enhances the therapeutic efficacy of immunogenic chemotherapy by stimulating type 1 interferon production by cancer cells. Cancer Res. 2015;75(18):3812\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1122. [publishedOnlineFirst:20150724].","journal-title":"Cancer Res"},{"issue":"2","key":"2974_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nri.2016.142","volume":"17","author":"J Jin","year":"2017","unstructured":"Jin J, He S. The complement system is also important in immunogenic cell death. Nat Rev Immunol. 2017;17(2):143. https:\/\/doi.org\/10.1038\/nri.2016.142. [publishedOnlineFirst:20161228].","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2974_CR42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/cdd.2017.15","volume":"24","author":"AD Garg","year":"2017","unstructured":"Garg AD, Vandenberk L, Fang S, et al. Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ. 2017;24(5):832\u201343. https:\/\/doi.org\/10.1038\/cdd.2017.15. [publishedOnlineFirst:20170224].","journal-title":"Cell Death Differ"},{"issue":"1","key":"2974_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.stem.2017.03.023","volume":"21","author":"JK Hu","year":"2017","unstructured":"Hu JK, Du W, Shelton SJ, et al. An FAK-YAP-mTOR signaling axis regulates stem cell-based tissue renewal in mice. Cell Stem Cell. 2017;21(1):91-106 e6. https:\/\/doi.org\/10.1016\/j.stem.2017.03.023. [published Online First: 2017\/05\/02].","journal-title":"Cell Stem Cell"},{"issue":"7827","key":"2974_CR44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","volume":"586","author":"KA Lawson","year":"2020","unstructured":"Lawson KA, Sousa CM, Zhang X, et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature. 2020;586(7827):120\u20136. https:\/\/doi.org\/10.1038\/s41586-020-2746-2. [publishedOnlineFirst:20200923].","journal-title":"Nature"},{"key":"2974_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcancer.2015.02.004","volume":"33","author":"O Kepp","year":"2015","unstructured":"Kepp O, Semeraro M, Bravo-San Pedro JM, et al. eIF2alpha phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol. 2015;33:86\u201392. https:\/\/doi.org\/10.1016\/j.semcancer.2015.02.004. [publishedOnlineFirst:20150306].","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2974_CR46","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487\u2013500. https:\/\/doi.org\/10.1038\/s41590-022-01132-2. [publishedOnlineFirst:20220210].","journal-title":"Nat Immunol"},{"issue":"2","key":"2974_CR47","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1172\/JCI94586[publishedOnlineFirst:2018\/01\/18]","volume":"128","author":"DMS Hossain","year":"2018","unstructured":"Hossain DMS, Javaid S, Cai M, et al. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest. 2018;128(2):644\u201354. https:\/\/doi.org\/10.1172\/JCI94586[publishedOnlineFirst:2018\/01\/18].","journal-title":"J Clin Invest"},{"key":"2974_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-100008. [publishedOnlineFirst:20121112].","journal-title":"Annu Rev Immunol"},{"issue":"17","key":"2974_CR49","doi-asserted-by":"publisher","first-page":"e2117065119","DOI":"10.1073\/pnas.2117065119","volume":"119","author":"D Ozmadenci","year":"2022","unstructured":"Ozmadenci D, Shankara Narayanan JS, Andrew J, et al. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis. Proc Natl Acad Sci U S A. 2022;119(17):e2117065119. https:\/\/doi.org\/10.1073\/pnas.2117065119. [publishedOnlineFirst:20220425].","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2974_CR50","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","volume":"18","author":"AN Gordon","year":"2000","unstructured":"Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18(17):3093\u2013100. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3093.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2974_CR51","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19):2811\u20138. https:\/\/doi.org\/10.1200\/JCO.2006.09.6735.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2974_CR52","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074. [publishedOnlineFirst:20220203].","journal-title":"Ann Oncol"},{"key":"2974_CR53","doi-asserted-by":"publisher","first-page":"103663","DOI":"10.1016\/j.critrevonc.2022.103663","volume":"173","author":"AE Boukouris","year":"2022","unstructured":"Boukouris AE, Theochari M, Stefanou D, et al. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: a 2022 update. Crit Rev Oncol Hematol. 2022;173:103663. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103663. [publishedOnlineFirst:20220326].","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2974_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54\u201361. https:\/\/doi.org\/10.1038\/nm1523. [publishedOnlineFirst:2006\/12\/26].","journal-title":"Nat Med"},{"key":"2974_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0047","author":"A Gulla","year":"2021","unstructured":"Gulla A, Morelli E, Samur MK, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation. Cancer Discov. 2021. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0047. [publishedOnlineFirst:2021\/07\/08].","journal-title":"Cancer Discov"},{"issue":"14","key":"2974_CR56","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","volume":"71","author":"SR Mattarollo","year":"2011","unstructured":"Mattarollo SR, Loi S, Duret H, et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 2011;71(14):4809\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0753. [publishedOnlineFirst:20110606].","journal-title":"Cancer Res"},{"issue":"1","key":"2974_CR57","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","volume":"163","author":"A Serrels","year":"2015","unstructured":"Serrels A, Lund T, Serrels B, et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell. 2015;163(1):160\u201373. https:\/\/doi.org\/10.1016\/j.cell.2015.09.001. [publishedOnlineFirst:2015\/09\/26].","journal-title":"Cell"},{"issue":"9","key":"2974_CR58","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14(9):598\u2013610. https:\/\/doi.org\/10.1038\/nrc3792. [publishedOnlineFirst:2014\/08\/08].","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2974_CR59","doi-asserted-by":"publisher","first-page":"B031","DOI":"10.1158\/2326-6066.Imm2016-b031","volume":"4","author":"JA Pachter","year":"2016","unstructured":"Pachter JA, Weaver DT. Abstract B031: FAK\/PYK2 inhibition enhances antitumor efficacy of anti-PD-1 and anti-4\u20131BB antibodies. Cancer Immunol Res. 2016;4(11):B031-B31. https:\/\/doi.org\/10.1158\/2326-6066.Imm2016-b031.","journal-title":"Cancer Immunol Res"},{"key":"2974_CR60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0308","author":"A Wang-Gillam","year":"2022","unstructured":"Wang-Gillam A, Lim KH, McWilliams R, et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I, dose escalation, and expansion study. Clin Cancer Res. 2022. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0308. [publishedOnlineFirst:20221013].","journal-title":"Clin Cancer Res"},{"key":"2974_CR61","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0192","author":"VE Lander","year":"2022","unstructured":"Lander VE, Belle JI, Kingston NL, et al. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Cancer Discov. 2022. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0192. [publishedOnlineFirst:20220927].","journal-title":"Cancer Discov"},{"issue":"5","key":"2974_CR62","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ccell.2015.04.001","volume":"27","author":"F Li","year":"2015","unstructured":"Li F, Han X, Li F, et al. lkb1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. Cancer Cell. 2015;27(5):698\u2013711. https:\/\/doi.org\/10.1016\/j.ccell.2015.04.001. [publishedOnlineFirst:2015\/05\/06].","journal-title":"Cancer Cell"},{"issue":"9","key":"2974_CR63","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105\u201311. https:\/\/doi.org\/10.1093\/bioinformatics\/btp120. [publishedOnlineFirst:2009\/03\/18].","journal-title":"Bioinformatics"},{"key":"2974_CR64","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/978-1-4939-3167-5_18","volume":"1374","author":"S Ghosh","year":"2016","unstructured":"Ghosh S, Chan CK. Analysis of RNA-Seq data using tophat and cufflinks. Methods Mol Biol. 2016;1374:339\u201361. https:\/\/doi.org\/10.1007\/978-1-4939-3167-5_18.","journal-title":"Methods Mol Biol"},{"issue":"W1","key":"2974_CR65","doi-asserted-by":"publisher","first-page":"W147","DOI":"10.1093\/nar\/gkw419","volume":"44","author":"S Babicki","year":"2016","unstructured":"Babicki S, Arndt D, Marcu A, et al. Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 2016;44(W1):W147\u201353. https:\/\/doi.org\/10.1093\/nar\/gkw419. [publishedOnlineFirst:2016\/05\/18].","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"2974_CR66","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48(W1):W488\u201393. https:\/\/doi.org\/10.1093\/nar\/gkaa216. [published Online First: 2020\/04\/05].","journal-title":"Nucleic Acids Res"}],"updated-by":[{"DOI":"10.1186\/s13046-024-03033-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-02974-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T02:08:09Z","timestamp":1713233289000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-02974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2974"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-02974-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2639424\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-024-03033-8","URL":"https:\/\/doi.org\/10.1186\/s13046-024-03033-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trial in this study was conducted following the Declaration of Helsinki and approved by the institutional review board of Cancer Hospital Chinese Academy of Medical Sciences (Beijing, China) according to Good Clinical Practices and applicable laws and regulations. All methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent.All animal studies were performed according to the protocols approved by the ethics committee of Shanghai Jiao Tong University School of Medicine (SJTU-SM) and conducted in accordance with AAALAC guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors revised and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.J., S.X., L.L., and Z.Q.W. are employees of InxMed. The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}